Whitehurst, David G. T. http://orcid.org/0000-0002-7890-6756
Mah, Cassandra http://orcid.org/0000-0002-1555-2292
Krebs, Emanuel http://orcid.org/0000-0002-6590-8728
Enns, Benjamin http://orcid.org/0000-0002-4865-1510
Socias, M. Eugenia http://orcid.org/0000-0003-2556-7049
Jutras-Aswad, Didier http://orcid.org/0000-0002-8474-508X
Le Foll, Bernard
Nosyk, Bohdan http://orcid.org/0000-0003-2513-3718
,
Funding for this research was provided by:
Canadian Institutes of Health Research (Multiple (see submission))
Article History
Accepted: 22 February 2023
First Online: 7 April 2023
Declarations
:
: David GT Whitehurst is a member of the EuroQol Group Association. The opinions expressed in this paper do not necessarily reflect the opinions of the EuroQol Group, or those of the EuroQol Research Foundation. M Eugenia Socias and Bernard Le Foll report grants from Indivior, outside the work described in this paper. Didier Jutras-Aswad reports grants from the Canadian Institutes of Health Research and Health Canada, related to the work described in this paper; and non-financial support from Cardiol Rx and Tetra Bio Pharma, outside the work described in this paper. The remaining authors (Cassandra Mah, Emanuel Krebs, Benjamin Enns, and Bohdan Nosyk) declare they have nothing to disclose.
: Each clinical site’s ethics committee approved the study. The randomized controlled trial was registered at ClinicalTrials.gov (NCT03033732) prior to enrollment.
: Informed consent was obtained from all individual participants included in the randomized controlled trial.
: Not applicable. No individuals are identifiable based on the information reported in this manuscript.